Status:
COMPLETED
Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Compare PET/CT and MRI for the early detection of bone metastases of prostate cancer: diagnostic performance and impact on the patient management.Determine the lowest cost strategy according to the pr...
Detailed Description
In patients with high risk prostate cancer and high PSA levels, PET/CT with fluoride (18F) and FLUOROCHOLINE (18F) and whole-body MRI will be performed within one month. Data of a 6 month follow-up a...
Eligibility Criteria
Inclusion
- Age \> 18
- Histologically proven prostate cancer.
- Abnormal plasmatic level of prostate specific antigen dating less than 3 months, initial Gleason score available
- Written informed consent.
Exclusion
- Other active cancer or bone infection.
- Chemotherapy or change in hormone therapy since the last PSA assay
- Contraindication to MRI without contrast agent (claustrophobia, pace maker, metallic foreign body, some cardiac valves). Metallic joint prostheses are NOT a contraindication.
- Allergic reaction to radiopharmaceuticals that will be used.
- Patient who seems not capable of staying in the gantry of the machines during the examinations without moving.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT01501630
Start Date
December 1 2011
End Date
December 1 2014
Last Update
October 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service Médecine Nucléaire - Hôpital TENON
Paris, France, 75020